AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04772456
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Trial: NCT04322890
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg, ivgtt, every 21day.
Trial: NCT04088149
Drug: GXNPC1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous ADSCs
Trial: NCT04097938
Drug: GLPG3667 oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3667 oral suspension
Trial: NCT04097938
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension
Trial: NCT04097938
Drug: GLPG3667 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3667 capsules
Trial: NCT02582775
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
Trial: NCT00551694
Drug: GSK256073A tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03707249
Drug: Ferric Carboxymaltose Injectable Product
RxNorm normalized name: ferric carboxymaltose Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
Trial: NCT03707249
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
Trial: NCT03969004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion over 30 minutes
Trial: NCT03467750
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
Trial: NCT03467750
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered.
Trial: NCT03094468
Drug: P-3058 (terbinafine hydrochloride 10%)
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
Trial: NCT03094468
Drug: Vehicle of P-3058
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
Trial: NCT00796367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00617942
Drug: Cohort 2 neo-adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
Trial: NCT00617942
Drug: Cohort 1 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
Trial: NCT00617942
Drug: Cohort 2 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
Trial: NCT01263652
Drug: Diclofenac hydroxyethylpyrrolidine
RxNorm normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM/PO
Trial: NCT00526214
Drug: celecoxib medication
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
Trial: NCT02350868
Drug: MPT0E028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
Trial: NCT01467531
Drug: GSK1265744
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg q24h
Trial: NCT04409262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV placebo matched to TCZ
Trial: NCT02500732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo capsule designed to blind the atomoxetine intervention
Trial: NCT04401813
Drug: IBI308 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received IBI310 combined with sintilizumab 200mg
Trial: NCT04504253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
Trial: NCT03970746
Drug: Keytruda Injectable Product
RxNorm normalized name: Keytruda Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
Trial: NCT03970746
Drug: Alimta Injectable Product
RxNorm normalized name: Alimta Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
Trial: NCT04223479
Drug: Probiotic Formula Capsule
RxNorm normalized name: Probiotic Formula Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
Trial: NCT04223479
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
Trial: NCT02386475
Drug: sinemet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
Trial: NCT01294319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01294319
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01294319
Drug: Combined
RxNorm normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00943566
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
Trial: NCT04501874
Drug: EMB-001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive comparator
Trial: NCT01593761
Drug: CG400549
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960mg QD at fed state approx 1 hour after meal
Trial: NCT01965600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg, TID, 3 days, 1 of 2 periods
Trial: NCT01965600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg, BID, 3 days, 1 of 2 periods
Trial: NCT03313297
Drug: AZD4017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
Trial: NCT03313297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01156636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00387621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
Trial: NCT04227678
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
Trial: NCT04046029
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
Trial: NCT04762810
Drug: Cyclophosphamide and glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
Trial: NCT04762810
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
Trial: NCT03493464
Drug: BR55
RxNorm normalized name: Band-Aid Ourtone BR55 Bandages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A novel targeted ultrasound contrast agent
Trial: NCT04146259
Drug: calcium carbonate and alphacalcidol
RxNorm normalized name: calcium acetate and magnesium carbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment for hypocalcemia
Trial: NCT02451137
Drug: Background Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
Trial: NCT01034345
Drug: Calcineurin inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
Trial: NCT02944604
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06593730
Drug: NRL001 cream 0.5%w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06593730
Drug: NRL001 cream 0.75%w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06593730
Drug: NRL001 cream 1.0%w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06593730
Drug: NRL001 cream 1.5%w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06593730
Drug: NRL001 cream 2.0%w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06593730
Drug: NRL001 cream 2.5%w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04300556
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone administered orally.
Trial: NCT01832753
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04392531
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care according to hospital protocol
Trial: NCT03616652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT02885506
Drug: Oral administration of P218 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
Trial: NCT02889861
Drug: IMCgp100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
Trial: NCT00911508
Drug: Rate or Rhythm Control Therapy
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg
Trial: NCT03846466
Drug: KHK4323 IV/S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV / Single administration
Trial: NCT03846466
Drug: KHK4323 SC/S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC / Single administration
Trial: NCT03846466
Drug: KHK4323 IV/M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV / Multiple administration
Trial: NCT03846466
Drug: Placebo IV/S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV / Single administration
Trial: NCT03846466
Drug: Placebo IV/M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV / Multiple administration
Trial: NCT03846466
Drug: Placebo SC/S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC / Single administration
Trial: NCT03648021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
Trial: NCT00001426
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00207831
Drug: Tegafur and Uracil
RxNorm normalized name: Tegafur and uracil only product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04835142
Drug: Double blind control period A140
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
Trial: NCT02335359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT02111473
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone 250 mg injection per 3-4 weeks for 6 months
Trial: NCT01519700
Drug: EP2006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be teated with EP2006
Trial: NCT01958944
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02337543
Drug: NEO6860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEO6860 is an NCE acting as a TRPV1 antagonist
Trial: NCT03299166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule once daily (QD)
Trial: NCT02337543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02305199
Drug: Hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
Trial: NCT02305199
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid containing Sodium chloride 9 g/L
Trial: NCT02567331
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
Trial: NCT00670254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application is identical to experimental arm
Trial: NCT00670254
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
Trial: NCT02254135
Drug: BEA 2180 BR - rising dose
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02254135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03510546
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study dose as per protocol.
Trial: NCT04469907
Drug: AZD9977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of AZD9977 under fasted conditions.
Trial: NCT02739906
Drug: Regular human insulin (Huminsulin® Normal)
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
Trial: NCT06243679
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with PD-1 inhibitors, up to 1 year.
Trial: NCT04281862
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Trial: NCT04281862
Drug: Topical Prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care topical drop treatment
Trial: NCT01341353
Drug: Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00648063
Drug: Femara® Tablets 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg, single dose fasting
Trial: NCT01096355
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04681443
Drug: Crystallized phenol application
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystallized phenol application into the sinus tract
Trial: NCT00887536
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
Trial: NCT00887536
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles
Trial: NCT01390376
Drug: DAAOI-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAAOI-1 2g
Trial: NCT01390376
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch pill